Commercial Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 4, 2026 BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease Related Stories Commercial Novo Nordisk to launch Ozempic for type 2 diabetes in US pharminent May 4, 2026 Commercial Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening pharminent May 1, 2026 Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch pharminent April 30, 2026
